Prostate cancer (metastatic, hormone-relapsed) - enzalutamide [ID683]: committee papers
Table of Contents
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer - Astellas
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Consultee submission - Prostate Cancer UK
06 - Consultee submission - Tackle Prostate Cancer
07 - Consultee submission - British Association of Urological Nurses
08 - Consultee submission - British Association of Urological Surgeons
09 - Consultee submission - British Uro-Oncology Group
10 - Consultee submission - NCRI RCP RCR ACP
11 - clinical expert personal perspective - CLARKE
12 - clinical expert personal perspective - JAIN
13 - clinical expert personal perspective - GUNN
14 - clinical expert personal perspective - WATSON
15 - Evidence Review Group report prepared by Aberdeen Health Technology Assessment Group
16 - Evidence Review Group report erratum
17 - Manufacturer factual accuracy check of Evidence Review Group report
Prostate cancer (metastatic, hormone-relapsed) - enzalutamide [ID683]: committee papers
11 June 2015 (7.27 Mb 7 sec) |
This page was last updated: 09 June 2015